3SOF

A few threads on this one Setravis (Just a heads up and thanks for all the great work on the site, as always). Memy is having another great day.

uc.

Ah!
I got out too soon!
Huge options (form 4s) exercised on 1-5
But that's what happens when you go in for an oil change and drive away in a new car.
Best of luck to you guys.
GMan

Setravis,
please merge all MEMY threads!!
thanks

MEMY upgrade

Company    Ticker    Brokerage Firm    Ratings Change    Price Target
Memory Pharma    MEMY    Fortis Bank    Hold » Buy    $6

Got in at 4.75 and feel that I may have made a mistake.
I went in without checking T and S for block prints (mainly just went with the trend)
After reading the information from this thread, it gave me a more positive inclination in my decision.
Hopefully this is the thread with the latest information.

Out at 4.71 took loss
Just have to stick with my discipline of exiting out when the price opens and closes below the 15 minute 8 sma.
Good luck long term holders.

This stock is hot !  Wait out the correction if any....... 

52wk Range: 0.84 - 4.94
Volume: 1,154,415
Avg Vol (3m): 444,148

Technicals
Record Price High

Last Price Quote is:
14.29%above 13-day MA
40.82%above 50-day MA
RS Rating: 98 

Fundamentals
Earnings Expected on Feb 20

Key Data:
Market Cap (M): $35.60 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: 02/20/2007
Last Analyst Rating: Buy

Below are the 6 Month and 3 Year charts

"MEMY" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.                                
All history on a stock pick in 1 thread is awesome.                              
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.          
Thank You....and good luck with all your trades....make some $$$                  

Press Release Source: Memory Pharmaceuticals Corp.


Memory Pharmaceuticals to Present at Bio CEO & Investor Conference 2007
Wednesday February 7, 5:14 pm ET


MONTVALE, N.J., Feb. 7 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that Jim Sulat, President and Chief Executive Officer, will provide a Company update at the Bio CEO & Investor Conference 2007 on Wednesday, February 14, 2007 at 12:45 p.m. ET, at the Waldorf=Astoria, New York City.

 
Interested parties may access a live audio webcast of the presentation by visiting the Investor Relations section of Memory Pharmaceuticals' website at http://www.memorypharma.com. An archived version of the webcast will be available at the same location through Wednesday, February 21, 2007.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders such as Alzheimer's disease, schizophrenia, depression and bipolar disorder. For additional information, please visit our website at http://www.memorypharma.com.

--------------------------------------------------------------------------------
Source: Memory Pharmaceuticals Corp.

Stock was clobbered today on the news that one of their pipeline drugs, MEM1003, showed no real results in its Phase 2a bipolar disorder trial. I think the stock was totally oversold today, as treatment for bipolar disorder was an afterthought of the drug, and it's original intention for treatment of Alzheimer's Disease is still being investigated.

Technically, RSI is showing this thing being really oversold. Any thoughts on this thing?

PS. Entered today at 2.16. Probably not a great entry, but I'll ride it out.

TODAY'S RELEASE:
MONTVALE, N.J., March 5 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY) today announced top-line data from the Phase 2a study of MEM 1003 in acute mania in bipolar disorder, which was conducted with funding support from the Stanley Medical Research Institute. An analysis of the primary and secondary outcome measures in the trial indicated that MEM 1003 did not prove effective for the treatment of bipolar mania. MEM 1003 was safe and generally well-tolerated in the study.

The multi-center, double-blind, randomized, placebo-controlled study evaluated the safety and efficacy of MEM 1003 for the treatment of acute mania in bipolar disorder. Eighty-four subjects were randomized to receive MEM 1003 or placebo for a 21-day treatment period, which was followed by an optional open-label four-week treatment period. The primary outcome measure was a comparison of the percentage of subjects in the placebo and MEM 1003 treatment groups with at least 50% improvement from baseline in the Young Mania Rating Scale (YMRS) at 21 days. The secondary outcome measures were the mean change from baseline in the YMRS, the Modified Clinical Global Impression - Bipolar Scale and the Montgomery-Asberg Depression Rating Scale at 21 days. None of these outcome measures was achieved.

There were no serious adverse events reported in the MEM 1003 treatment group during the study, in contrast to three serious adverse events of worsening of mania reported in the placebo treatment group. The most commonly reported adverse events in the MEM 1003 treatment arm of the trial were headache, gastrointestinal effects and pruritus (or itching).

"We are obviously disappointed that MEM 1003 did not prove effective in the treatment of mania in our study," said Stephen R. Murray, M.D., Ph.D., Vice President of Clinical Development. "However, the target symptoms and the nature of the assessments in our ongoing Phase 2a study in Alzheimer's disease are very different from those in this mania study, and we do not believe that the negative results in this study are predictive of the effects of MEM 1003 in Alzheimer's disease."

"Memory Pharmaceuticals has completed a high quality study," said Gary S. Sachs, M.D., Associate Professor in Psychiatry, Harvard Medical School and Director, Bipolar Mood Disorder Program at Massachusetts General Hospital and Principal Investigator on the Phase 2a trial of MEM 1003 in bipolar disorder. "Although the maximum dose allowed in the study proved well-tolerated, the results clearly showed no difference in efficacy endpoints at day 21 between MEM 1003 and placebo."

"We are committed to finishing the ongoing Phase 2a study in Alzheimer's disease and expect results in the fourth quarter of this year," said David A. Lowe, Ph.D., Chief Scientific Officer. "We are currently completing a full analysis of the bipolar results in order to learn as much as we can from this data set."

About MEM 1003

MEM 1003, a CNS-optimized dihydropyridine, is a neuronal L-type calcium channel modulator. MEM 1003 was found to be generally safe and well tolerated in Phase 1a and 1b clinical trials in 125 healthy volunteers in the United Kingdom and a Phase 1b safety and tolerability study in 81 Alzheimer's patients under a U.S. Investigational New Drug Application. The Company is currently conducting a multi-center, randomized, double-blind, placebo- controlled Phase 2a study to evaluate the safety and efficacy of MEM 1003 in Alzheimer's disease.

MEMY making another notable move to the upside today as it may have bottomed at the 200SMA 

AH market @ 2.15 bid & 2.38 ask 

Monday will be BO!!
cheers
Oliver

Memory Pharmaceuticals Completes Enrollment in Phase 2a MEM 1003 Alzheimer's Disease Trial
Thursday April 5, 4:05 pm ET

MONTVALE, N.J., April 5 /PRNewswire-FirstCall/ -- Memory Pharmaceuticals Corp. (Nasdaq: MEMY - News) today announced that it has completed enrollment in its Phase 2a trial of MEM 1003 in Alzheimer's disease. The Company expects to report top-line results for this trial in the fourth quarter of 2007.

"Completion of enrollment in this trial is a key milestone in our Alzheimer's disease programs," said Stephen R. Murray, M.D., Ph.D., Vice President of Clinical Development. "We are excited that the MEM 1003 Phase 2a trial is nearing completion and are focused on reporting top-line results from both this trial, and our ongoing Phase 2a trial of MEM 3454 for Alzheimer's disease, in the fourth quarter of this year."

This Phase 2a clinical trial is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of two dose levels of MEM 1003 in approximately 180 subjects with mild to moderate Alzheimer's disease at over 50 centers in the United States. Subjects participating in the study were randomized at enrollment into one of three treatment groups -- 30 mg of MEM 1003 twice a day, 90 mg of MEM 1003 twice a day or placebo twice a day. During the double-blind treatment segment of the study, subjects receive MEM 1003 or placebo for a period of 12 weeks, which is followed by a four week single-blind placebo treatment. The primary outcome measure of the trial is a twelve-week change in the Alzheimer's Disease Assessment Scale -- Cognitive subscale (ADAS - cog) score. Secondary measures will assess changes in activities of daily living, behavior and global function.

MEM 1003 is a neuronal L-type calcium channel modulator that Memory Pharmaceuticals is developing for the treatment of Alzheimer's disease. By blocking L-type calcium channels, MEM 1003 may regulate the flow of calcium and reestablish normal levels of calcium, which may help treat and prevent the onset of Alzheimer's disease.

(MEMY)
Memory Shares Hit 52-Week Low on Monday
After Alzheimer's Trial Fails to Meet Endpoint
Shares of Memory Pharmaceuticals Corp. (MEMY) hit a 52-week low on
Monday after a Phase IIa study of MEM 1003 for Alzheimer's disease
failed to meet its primary endpoint, which was a twelve-week mean
change in the Alzheimer's disease Assessment Scale- Cognitive subscale
(ADAS-cog) score in the overall population. There were seven
treatment-emergent serious adverse events in five subjects, including
two deaths. The trial enrolled 183 subjects with mild to moderate
Alzheimer's disease and included monotherapy subjects and subjects
on stable doses of cholinesterase inhibitors. In the subgroup of subjects
receiving cholinesterase inhibitors, the change in ADAS-cog favored
treatment over placebo, although this difference was not statistically
significant. "While we are disappointed that the trial did not meet the
primary endpoint, we are encouraged by the favorable trend seen in the
subgroup of subjects receiving cholinesterase inhibitors," said Stephen
R. Murray, M.D., Ph.D., Chief Medical Officer. Memory Pharmaceuticals
is focused on developing drugs for the treatment of debilitating central
nervous system disorders. Two named drug candidates in its nicotinic
alpha-7 agonist program are MEM 3454 and MEM 63908. A Phase
2a clinical trial of MEM 3454 in Alzheimer's disease is currently being
conducted. The Company plans to commence a Phase 2a clinical trial
of MEM 3454 in cognitive impairment associated with schizophrenia
(CIAS) in the fourth quarter of 2007. Dr. Murray said in a conference call
on Monday, "The recruitment and progress for our MEM 3454 Alzheimer's
study has been extremely satisfactory. We have not experienced
any difficulty in finding subjects, which was more of a problem in the
MEM 1003 trial." As of June 30, 2007, the Company had an accumulated
deficit of $200.9 million and cash of $51.3 million.

Anyone still in MEMY?

I got a few down here, thinking risk/reward is favourable for a swing trade.


Cheers

Share of Memory Pharmaceuticals Higher
After Roche Exercises Option for MEM 3454
Shares of Memory Pharmaceuticals Corp (MEMY) got a boost on Friday
after Roche exercised its option to further develop and commercialize
Memory Pharmaceuticals lead nicotinic alpha-7 agonist drug candidate,
MEM 3454, for neurological and psychiatric disorders. Roche's exercise
of its option for MEM 3454 triggers a $6 million milestone payment and
entitles Memory Pharmaceuticals to future payments upon the achievement
of additional milestones and royalties on product sales, including
a $17 million milestone payment upon the completion of the ongoing
Phase 2a study in cognitive impairment associated with schizophrenia
(CIAS). In addition, Memory Pharmaceuticals retains an option to co-promote
MEM 3454 in the United States. In a recently completed Phase
2a study in Alzheimer's disease patients, MEM 3454 demonstrated a
statistically significant effect on multiple measures of cognition. The
compound is currently being evaluated in a Phase 2a trial in CIAS, with
top-line results expected in the fourth quarter of 2008. In addition, Memory
Pharmaceuticals and Roche recently expanded their schizophrenia
development program for MEM 3454 to include a biomarker study,
which will be funded by Roche. Memory Pharmaceuticals expects to
initiate the biomarker trial this summer, with results expected by early
2009. The President and CEO of Memory Pharmaceuticals, Vaughn M.
Kailian, added in a conference call today, "This is a major milestone for
the company and validates the value of this potential drug candidate. It
also strengthens our immediate and long-term financial position."

Share of Memory Pharmaceuticals Higher
After Roche Exercises Option for MEM 3454
Shares of Memory Pharmaceuticals Corp (MEMY) got a boost on Friday
after Roche exercised its option to further develop and commercialize
Memory Pharmaceuticals lead nicotinic alpha-7 agonist drug candidate,
MEM 3454, for neurological and psychiatric disorders. Roche's exercise
of its option for MEM 3454 triggers a $6 million milestone payment and
entitles Memory Pharmaceuticals to future payments upon the achievement
of additional milestones and royalties on product sales, including
a $17 million milestone payment upon the completion of the ongoing
Phase 2a study in cognitive impairment associated with schizophrenia
(CIAS). In addition, Memory Pharmaceuticals retains an option to co-promote
MEM 3454 in the United States. In a recently completed Phase
2a study in Alzheimer's disease patients, MEM 3454 demonstrated a
statistically significant effect on multiple measures of cognition. The
compound is currently being evaluated in a Phase 2a trial in CIAS, with
top-line results expected in the fourth quarter of 2008. In addition, Memory
Pharmaceuticals and Roche recently expanded their schizophrenia
development program for MEM 3454 to include a biomarker study,
which will be funded by Roche. Memory Pharmaceuticals expects to
initiate the biomarker trial this summer, with results expected by early
2009. The President and CEO of Memory Pharmaceuticals, Vaughn M.
Kailian, added in a conference call today, "This is a major milestone for
the company and validates the value of this potential drug candidate. It
also strengthens our immediate and long-term financial position."